Johnson & Johnson (J&J) and Bayer HealthCare are facing an increasing number of lawsuits from numerous individuals alleging excessive bleeding episodes related to Xarelto. One of the most recent cases is from a woman in Arkansas who started taking Xarelto in April 2015. She believed at that time that the medication would increase her longevity and was not aware of any potentially deadly side effects.
Xarelto Lawsuit Overview
The plaintiff was prescribed Xarelto (rivaroxaban) to prevent stroke and claimed she followed the appropriate instructions. However, on July 4, 2015, the plaintiff suffered life-threatening bleeding due to Xarelto and had to be hospitalized because of these injuries. The plaintiff was subsequently taken off Xarelto a few days after her internal bleeding episode and was released from hospitalization after several nights of observation.
The plaintiff is filing this Xarelto lawsuit alleging the pharmaceutical giants knew or should have known of these complications but neglected to warn the public. She is filing legal action for multiple counts of negligence and failure to warn.
In addition, the plaintiff said that had she been aware of the potentially life-threatening bleeding that developed as a result of using Xarelto, she never would have taken the medication. This lawsuit is in the U.S. District Court for the District of Eastern Louisiana as part of a multidistrict litigation (MDL).
MDLs are frequently used for complex lawsuits in the interest of efficiency by consolidating lawsuits to be held in one court before one judge. This streamlines the process and helps to minimize court costs.
Xarelto Bleeding Complications
The anticoagulant Xarelto was brought to market in 2011 by Johnson & Johnson in collaboration with Bayer HealthCare. Xarelto’s competition was its predecessor, Pradaxa that was released in 2010. Pradaxa was the first blood thinner to be released since warfarin (brand name Coumadin) was made available in the 1950s. Following Pradaxa, additional pharmaceutical companies had started to develop their own anticoagulants to try to join the lucrative blood thinner market.
National law firm Parker Waichman has extensive and successful experience representing clients in pharmaceutical litigation. Attorneys at the firm are available to answer any questions for individuals seeking information about filing a potential lawsuit.
Anticoagulants work by inhibiting the body’s blood clotting mechanism to increase circulation efficiency and to avoid possibly fatal blood clots. The problems arise, however, because blood thinners also inhibit the body’s ability to heal itself from internal bleeding episodes.
Xarelto, Pradaxa, and Eliquis are included in the class of new generation anticoagulants, that rapidly gained in popularity as a result of being promoted as more convenient and efficient than warfarin. Doctors were able to prescribe them in daily standardized dosages. They also did not need frequent dose adjustments with mandatory blood monitoring, or dietary restriction that the established warfarin has.
Unlike warfarin that has an available antidote, at this point, the newer blood thinners have no known antidote or treatment to quickly restore clotting ability in the event of an internal bleeding episode, the need for emergency surgery, or a serious accident.
Life-threatening bleeding from Xarelto was reported shortly after its release. People taking Xarelto alleged they had to be hospitalized for these problems and had no prior indication of this possibility.
There are currently over 11,000 Xarelto lawsuits pending in courts all over the United States. It is likely that plaintiffs will use the information that has been gathered by ProPublica, a public interest news organization, and others to aid their claims that drug manufacturers boosted the benefits of Xarelto while minimizing the alleged potential side effects.
Independent studies have noted it would have been beneficial, especially for the elderly, if blood monitoring had been part of the newer generation drugs’ regimen. This would help to identify those who may be more at risk for excessive, possibly life-threatening, uncontrollable bleeding.
Dr. Rita Redberg, a professor of cardiology at the University of California, San Francisco noted, “There have been deaths reported of people who have had trauma and were on one of these new anticoagulants, and they were not able to be reversed.”
Some plaintiffs allege Xarelto was brought to market too quickly without sufficient testing for safety and efficacy.
Legal Help for Xarelto Users
If you or someone you know suffered adverse side effects, such as uncontrollable bleeding due to the use of Xarelto, you may have valuable legal rights. The attorneys at Parker Waichman offer free, no-obligation case evaluations. For more information, contact our personal injury lawyers at 1-800-YOURLAWYER (1-800-968-7529).